What Is 3-Hydroxy-3-methylglutaryl-CoA lyase

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 15, 2026

Quick Answer: 3-Hydroxy-3-methylglutaryl-CoA lyase (HMG-CoA lyase) is an enzyme that catalyzes the cleavage of HMG-CoA into acetoacetate and acetyl-CoA, a critical step in ketogenesis and leucine catabolism. Deficiency in this enzyme causes a rare autosomal recessive metabolic disorder known as HMG-CoA lyase deficiency, first described in 1976.

Key Facts

HMG-CoA lyase deficiency was first reported in 1976 by Björkhem et al.
The enzyme catalyzes the conversion of HMG-CoA into acetoacetate and acetyl-CoA.
HMG-CoA lyase is encoded by the HMGCL gene located on chromosome 1 (1p36.11).
Over 70 mutations in the HMGCL gene have been linked to the deficiency.
The disorder affects ketone body formation and leucine metabolism simultaneously.

Overview

3-Hydroxy-3-methylglutaryl-CoA lyase (HMG-CoA lyase) is a mitochondrial enzyme essential for both ketogenesis and the catabolism of the amino acid leucine. It plays a pivotal role in energy production during fasting by enabling the liver to generate ketone bodies used by the brain and other tissues.

The enzyme is encoded by the HMGCL gene, located on chromosome 1 at position 1p36.11, and functions exclusively within mitochondria. Mutations in this gene lead to a rare autosomal recessive disorder known as HMG-CoA lyase deficiency, which disrupts normal metabolic pathways.

Primary function: HMG-CoA lyase cleaves 3-hydroxy-3-methylglutaryl-CoA into acetoacetate and acetyl-CoA, a reaction critical for ketone body synthesis.
Metabolic pathway: It operates in the final step of ketogenesis and in the degradation pathway of leucine, one of the branched-chain amino acids.
Gene location: The HMGCL gene is found on the short arm of chromosome 1 at cytogenetic position 1p36.11.
Enzyme localization: The enzyme functions within the mitochondrial matrix, where ketogenesis and amino acid breakdown occur.
Discovery: HMG-CoA lyase deficiency was first described in a clinical case study published in 1976 by Björkhem and colleagues.

How It Works

The mechanism of HMG-CoA lyase involves a precise biochemical cleavage reaction that supports energy homeostasis, especially during periods of low glucose availability. Each step is tightly regulated and dependent on mitochondrial integrity and substrate availability.

Substrate binding:HMG-CoA binds to the active site of the enzyme, initiating a conformational change that prepares it for cleavage.
Cleavage reaction: The enzyme catalyzes a carbon-carbon bond breakage, yielding acetoacetate (a ketone body) and acetyl-CoA as end products.
Role in ketogenesis: This step is the final reaction in the production of ketone bodies, making it indispensable during fasting or low-carbohydrate states.
Leucine metabolism: In the leucine catabolic pathway, HMG-CoA lyase acts after 3-methylglutaconyl-CoA is hydrated to form HMG-CoA.
Energy production: The acetyl-CoA generated can enter the citric acid cycle to produce ATP, supporting cellular energy needs.
Regulation: The enzyme is not regulated by hormones directly but is influenced by substrate concentration and mitochondrial health.

Comparison at a Glance

Below is a comparison of HMG-CoA lyase with other key enzymes in related metabolic pathways to highlight its unique role.

Enzyme	Pathway	Substrate	Product(s)	Genetic Disorder
HMG-CoA lyase	Ketogenesis, Leucine catabolism	HMG-CoA	Acetoacetate + Acetyl-CoA	HMG-CoA lyase deficiency
HMG-CoA synthase	Ketogenesis	Acetyl-CoA	HMG-CoA	Ketogenesis deficiency (rare)
Phenylalanine hydroxylase	Phenylalanine metabolism	Phenylalanine	Tyrosine	Phenylketonuria
MCAD	Fatty acid oxidation	Octanoyl-CoA	Acyl-CoA derivatives	MCAD deficiency
Propionyl-CoA carboxylase	Odd-chain fatty acid metabolism	Propionyl-CoA	Methylmalonyl-CoA	Propionic acidemia

While several enzymes contribute to mitochondrial metabolism, HMG-CoA lyase uniquely bridges amino acid breakdown and ketone synthesis. Unlike MCAD or phenylalanine hydroxylase, its deficiency affects both energy production and protein metabolism, leading to complex clinical presentations including metabolic acidosis and hypoglycemia.

Why It Matters

Understanding HMG-CoA lyase is crucial for diagnosing and managing rare metabolic disorders and for advancing research in mitochondrial diseases. Its dual role in metabolism makes it a key target for biochemical and genetic studies.

Diagnostic importance: Newborns with HMG-CoA lyase deficiency may present with lethargy and vomiting, requiring prompt identification via tandem mass spectrometry.
Clinical symptoms: Untreated cases can lead to hypoglycemia, metabolic acidosis, and liver dysfunction, often triggered by fasting or illness.
Genetic screening: Over 70 mutations in the HMGCL gene have been documented, aiding in carrier testing and prenatal diagnosis.
Treatment approach: Management includes avoiding prolonged fasting and restricting dietary leucine intake to prevent toxic metabolite accumulation.
Research implications: Studying this enzyme helps clarify the integration of amino acid and lipid metabolism in human physiology.
Therapeutic development: Gene therapy and enzyme replacement strategies are being explored for inherited metabolic disorders like this one.

Early diagnosis and dietary intervention significantly improve outcomes for patients with HMG-CoA lyase deficiency. Continued research into mitochondrial enzymes promises better treatments and deeper insights into human metabolism.